Clinical Trials

762 enrolled 14 charts

Breast Neoplasms

NCT00841828 2023-03-31

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

102 enrolled 10 charts

Breast Neoplasms

NCT01036087 2023-03-30

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

47 enrolled 13 charts

Phase 2 Active not recruiting

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT02315196 2023-03-29

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

62 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01779050 2022-11-01

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

7 enrolled 8 charts

Breast Neoplasms

NCT00087178 2022-08-11

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

2,722 enrolled 14 charts

Breast Neoplasms

NCT03556358 2022-01-14

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

809 enrolled 14 charts

Breast Neoplasms

NCT00193206 2021-11-23

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

123 enrolled 8 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00193050 2021-10-26

Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer

110 enrolled 8 charts

Breast Neoplasms

NCT00464646 2021-10-25

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

105 enrolled 17 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01593020 2021-09-22

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

54 enrolled 10 charts

Breast Neoplasms

NCT01220128 2021-05-25

INDUCT

66 enrolled 40 charts

Breast Neoplasms

NCT00513292 2019-01-23

Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

280 enrolled 12 charts

Breast Neoplasms

NCT00559845 2018-04-09

A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer

56 enrolled 10 charts

Breast Neoplasms

NCT00950300 2018-01-23

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

596 enrolled 31 charts 1 FDA

Breast Neoplasms

NCT00176488 2017-03-23

Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

31 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00499603 2016-11-01

Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer

Phase 2 Unknown

62 enrolled 13 charts

Breast Neoplasms

NCT00429299 2016-03-22

CHERLOB

121 enrolled 16 charts

Breast Neoplasms

NCT00322374 2016-03-10

Phase I Combination w/ Epirubicin

Phase 1 Completed

42 enrolled 24 charts

Breast Neoplasms

NCT00756470 2014-11-17

Phase II Neoadjuvant in Inflammatory Breast Cancer

15 enrolled 10 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00270894 2012-03-20

Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients

30 enrolled 11 charts